Corvus Pharmaceuticals
A Proven Leader in Cutting Edge Oncological Solutions
Market Cap: $327,740,000
P/B: 5.87x
Net Debt: +$43,060,000
EV: $284,680,000
Shares Outstanding: 77,110,000
Business Overview
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company, founded in 2014, focused on developing innovative therapies designed to transform the treatment of immune-mediated diseases and cancer. The company’s lead candidate, Soquelitinib, is a first-in-class, oral ITK (interleukin-2–inducible T-cell kinase) inhibitor that uniquely modulates multiple immune signaling pathways.
Soquelitinib is designed to rebalance the immune system by selectively suppressing inflammatory T-cell subsets (Th2 and Th17) while enhancing cancer-fighting Th1 responses. Notably, the drug facilitates the conversion of pathogenic Th17 cells into regulatory T cells (Tregs), which play a critical role in reducing autoimmunity and chronic inflammation.
The therapeutic impact of Soquelitinib is further underscored by its ability to block a range of interleukins, including IL-4, IL-5, IL-9, IL-13, IL-17, IL-21, and IL-22. These interleukins are implicated in various autoimmune and inflammatory disorders, significantly broadening Soquelitinib’s potential clinical utility across both oncology and immunology.
